Claims for Patent: 10,093,934

Summary for Patent: 10,093,934

Title:	SDF-1 binding nucleic acids and the use thereof in cancer treatment
Abstract:	The present invention is related to a nucleic acid molecule capable of binding to SDF-1, preferably capable of inhibiting SDF-1, whereby the nucleic acid molecule is for use in a method for the treatment and/or prevention of a disease or disorder, for use in a method for the treatment of a subject suffering from a disease or disorder or being at risk of developing a disease or disorder as an adjunct therapy, or for use as a medicament for the treatment and/or prevention of a disease or disorder, whereby the disease or disorder is cancer.
Inventor(s):	Purschke; Werner (Berlin, DE), Jarosch; Florian (Berlin, DE), Eulberg; Dirk (Berlin, DE), Klussmann; Sven (Berlin, DE), Buchner; Klaus (Berlin, DE), Maasch; Christian (Berlin, DE), Dinse; Nicole (Berlin, DE), Zboralski; Dirk (Berlin, DE)
Assignee:	NOXXON Pharma AG (Berlin, DE)
Application Number:	15/201,477
Patent Claims:	1. A method for the treatment of a subject suffering from cancer, wherein the method comprises a) administering to the subject a pharmaceutically effective amount of a type B L-nucleic acid, or a homolog thereof, that binds SDF-1, wherein said type B L-nucleic acid comprises, in order, a 5' flanking sequence, SEQ ID NO:52 and a 3' flanking sequence, wherein said 5' and 3' flanking sequences can hybridize to each other. 2. The method according to claim 1, wherein the method further comprises b) irradiating the subject, conducting surgery on said subject, exposing said subject to a cellular therapy and/or administering a pharmaceutically effective amount of a further pharmaceutically active agent to the subject. 3. The method of claim 1, wherein the cancer comprises a hematological cancer or a solid tumor. 4. The method of claim 2, wherein said L-nucleic acid is administered as an adjunct therapy or part of an adjunct therapy, with a primary treatment. 5. The method of claim 3, wherein said hematological cancer comprises leukemia or myeloma. 6. The method of claim 3, wherein said solid tumor comprises glioblastoma, colorectal cancer, breast cancer, lymphoma, prostate cancer, pancreatic cancer, renal cancer, ovarian cancer or lung cancer. 7. The method of claim 4, wherein the adjunct therapy sensitizes the subject to said primary treatment. 8. The method of claim 4, wherein said primary treatment comprises administrating a further pharmaceutically active agent to said subject, irradiating the subject, conducting surgery on said subject and/or exposing said subject to a cellular therapy. 9. The method of claim 8, wherein the further pharmaceutically active agent is selected from the group consisting of an antibody, an alkylating agent, an anti-metabolite, a plant alkaloid, a plant terpenoid, and a topoisomerase inhibitor. 10. The method of claim 8, wherein said further pharmaceutically active agent is selected from the group consisting of leucovorin, methotrexate, tamoxifen, sorafenib, lenalidomide, bortezomib, dexamethasone, flurouracil and prednisone. 11. The method of claim 9, wherein the antibody is selected from the group consisting of Rituximab, Ofatumumab, Cetuximab, Ibritumomab-Tiuxetan, Tositumomab, Trastuzumab, Bevacizumab, and Alemtuzumab. 12. The method of claim 9, wherein the alkylating agent is selected from the group consisting of cisplatin, carboplatin, oxaliplatin, mechlorethamine, cyclophosphamide, chlorambucil, doxorubicin, lioposomal doxorubicin, bendamustine, temozolomide and melphalan. 13. The method of claim 9, wherein the anti-metabolite is selected from the group consisting of purineazathioprine, mercaptopurine, fludarabine, pentostatin, and cladribine. 14. The method of claim 9, wherein the plant terpenoid comprises a taxane. 15. The method of claim 9, wherein the topoisomerase inhibitor is selected from the group consisting of camptothecin, irinotecan, and mitoxantrone. 16. The method of claim 1, wherein the L-nucleic acid comprises a modification. 17. The method of claim 16, wherein the modification is selected from the group consisting of an HES moiety, a PEG moiety, biodegradable modifications and combinations thereof. 18. The method of claim 16, wherein said modification enhances residence time in an animal or human host.

Details for Patent 10,093,934

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2030-09-09
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2030-09-09
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2030-09-09
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	05/07/2001		2030-09-09